Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Rüschoff

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Current Oncology (Toronto, Ont.)|December 23, 2021
The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An OverviewKorinna Jöhrens, Josef Rüschoff
Archives of Pathology & Laboratory Medicine|January 27, 2026
Filling in the Gaps of Examining Human Epidermal Growth Factor Receptor 2 (HER2)-Low and HER2-Ultralow in Breast Cancer: Clone Choice, Sample Size, and Reevaluating Scores Made on Archived SamplesJosef Rüschoff, Guiseppe Viale
Pathology|October 14, 2003
Re: Quantitative evaluation of AgNORs in bone tumoursGiovanni Tuccari, Dietmar Ofner, Josef Rüschoff
Breast Care (Basel, Switzerland)|September 9, 2010
Development of Targeted Therapies in ErbB2-Positive Breast CancerChristian Jackisch, Josef Rüschoff, Axel Ullrich
Pathologie (Heidelberg, Germany)|November 19, 2024
[Microsatellite instability-What should be considered in routine examinations?]Wolfgang Dietmaier, Daniela Hirsch, Josef Rüschoff
Onkologie|May 1, 2010
[HER2 testing and targeted therapy in advanced gastric cancer]Thomas Höhler, Josef Rüschoff, Karsten Ridwelski, et al.
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Current Opinion in Oncology|June 7, 2019
Human epidermal growth factor receptor 2-positive digestive tumorsAnna D Wagner, Berna C Özdemir, Josef Rüschoff
Cancer|March 2, 2024
Mismatch repair and microsatellite instability-Recommendation for an optimal test strategyJosef Rüschoff, Wolfgang Dietmaier, Tina Bocker Edmonston, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Current Oncology (Toronto, Ont.)|December 23, 2021
The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An OverviewKorinna Jöhrens, Josef Rüschoff
Archives of Pathology & Laboratory Medicine|January 27, 2026
Filling in the Gaps of Examining Human Epidermal Growth Factor Receptor 2 (HER2)-Low and HER2-Ultralow in Breast Cancer: Clone Choice, Sample Size, and Reevaluating Scores Made on Archived SamplesJosef Rüschoff, Guiseppe Viale
Pathology|October 14, 2003
Re: Quantitative evaluation of AgNORs in bone tumoursGiovanni Tuccari, Dietmar Ofner, Josef Rüschoff
Breast Care (Basel, Switzerland)|September 9, 2010
Development of Targeted Therapies in ErbB2-Positive Breast CancerChristian Jackisch, Josef Rüschoff, Axel Ullrich
Pathologie (Heidelberg, Germany)|November 19, 2024
[Microsatellite instability-What should be considered in routine examinations?]Wolfgang Dietmaier, Daniela Hirsch, Josef Rüschoff
Onkologie|May 1, 2010
[HER2 testing and targeted therapy in advanced gastric cancer]Thomas Höhler, Josef Rüschoff, Karsten Ridwelski, et al.
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Current Opinion in Oncology|June 7, 2019
Human epidermal growth factor receptor 2-positive digestive tumorsAnna D Wagner, Berna C Özdemir, Josef Rüschoff
Cancer|March 2, 2024
Mismatch repair and microsatellite instability-Recommendation for an optimal test strategyJosef Rüschoff, Wolfgang Dietmaier, Tina Bocker Edmonston, et al.
Pageof 13